CVS Health Corporation (CVS)
CVS Health (CVS) Upgraded to Buy: What Does It Mean for the Stock?
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why CVS Health (CVS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why CVS Health (CVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts to maintain its dominance over Novo Nordisk in the blockbuster weight loss drug market, as it puts the two drugmakers on equal footing on major drug plans.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why CVS Health (CVS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Sale Of Omnicare Long-Term Care Pharmacy Continues Portfolio Revamp
A bankruptcy court has approved the sale of CVS Health's underperforming Omnicare long-term care pharmacy network to GenieRx in a deal valued at $250 million.
CVS Health (CVS) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why CVS Health (CVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health: Still Cheap And Signs Of Improvement
CVS Health Corporation remains deeply undervalued despite persistent headwinds and an 11-year correction, with intrinsic value estimates well above current prices. Q1 2026 results showed 6.2% revenue growth and a 63.1% EPS increase, prompting management to raise full-year guidance for revenue, cash flow, and earnings. Margins and the medical benefit ratio are showing early signs of recovery, supporting management's and analysts' renewed optimism for double-digit EPS growth.
